Chimerix Revenue 2011-2018 | CMRX
Chimerix revenue from 2011 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| Chimerix Annual Revenue (Millions of US $) |
|
|---|---|
| 2018 | $7 |
| 2017 | $4 |
| 2016 | $6 |
| 2015 | $11 |
| 2014 | $4 |
| 2013 | $4 |
| 2012 | $34 |
| 2011 | $12 |
| 2010 | $2 |
| Chimerix Quarterly Revenue (Millions of US $) |
|
|---|---|
| Q4 2018 | $5 |
| Q3 2018 | $0 |
| Q2 2018 | $1 |
| Q1 2018 | $1 |
| Q4 2017 | $2 |
| Q3 2017 | $1 |
| Q2 2017 | $1 |
| Q1 2017 | $1 |
| Q4 2016 | $2 |
| Q3 2016 | $1 |
| Q2 2016 | $2 |
| Q1 2016 | $1 |
| Q4 2015 | $3 |
| Q3 2015 | $2 |
| Q2 2015 | $4 |
| Q1 2015 | $1 |
| Q4 2014 | $1 |
| Q3 2014 | $1 |
| Q2 2014 | $1 |
| Q1 2014 | $1 |
| Q4 2013 | $1 |
| Q3 2013 | $1 |
| Q2 2013 | $1 |
| Q1 2013 | $2 |
| Q4 2012 | $4 |
| Q3 2012 | $21 |
| Q2 2012 | $6 |
| Q1 2012 | $3 |
| Q4 2011 | $0 |
| Q4 2010 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.133B | $0.007B |
| Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $129.838B | 25.32 |
| Medtronic (MDT) | Ireland | $112.952B | 16.51 |
| Stryker (SYK) | United States | $67.256B | 24.66 |
| Boston Scientific (BSX) | United States | $48.820B | 23.72 |
| Baxter (BAX) | United States | $37.991B | 24.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.550B | 15.71 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.615B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.912B | 0.00 |
| ResMed (RMD) | United States | $14.218B | 26.96 |
| Aurora Cannabis (ACB) | Canada | $9.118B | 64.29 |
| Bio-Rad Laboratories (BIO) | United States | $8.765B | 50.28 |
| Perrigo (PRGO) | Ireland | $6.633B | 10.75 |
| Hill-Rom Holdings (HRC) | United States | $6.374B | 19.72 |
| Insulet (PODD) | United States | $4.900B | 1642.60 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.701B | 0.00 |
| ICU Medical (ICUI) | United States | $4.568B | 28.29 |
| Haemonetics (HAE) | United States | $4.189B | 37.16 |
| Hutchison China MediTech (HCM) | China | $4.046B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.268B | 0.00 |
| Neogen (NEOG) | United States | $2.958B | 48.10 |
| NuVasive (NUVA) | United States | $2.784B | 24.18 |
| Quidel (QDEL) | United States | $2.365B | 21.17 |
| National Vision Holdings (EYE) | United States | $2.220B | 43.66 |
| Aphria (APHA) | $1.917B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.349B | 19.38 |
| VAREX IMAGING (VREX) | United States | $1.222B | 23.93 |
| Cardiovascular Systems (CSII) | United States | $1.190B | 854.00 |
| AtriCure (ATRC) | United States | $1.049B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.931B | 25.16 |
| Omeros (OMER) | United States | $0.908B | 0.00 |
| PetIQ (PETQ) | United States | $0.862B | 24.67 |
| MacroGenics (MGNX) | United States | $0.791B | 0.00 |
| Cerus (CERS) | United States | $0.787B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.737B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.689B | 0.00 |
| Evolus (EOLS) | United States | $0.681B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.666B | 22.66 |
| OraSure Technologies (OSUR) | United States | $0.594B | 25.86 |
| Surmodics (SRDX) | United States | $0.546B | 79.43 |
| LeMaitre Vascular (LMAT) | United States | $0.536B | 25.46 |
| Meridian Bioscience (VIVO) | United States | $0.531B | 15.82 |
| Quanterix (QTRX) | United States | $0.492B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.322B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.321B | 20.88 |
| Insys Therapeutics (INSY) | United States | $0.313B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.305B | 125.85 |
| Vapotherm (VAPO) | United States | $0.296B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.271B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.213B | 2.91 |
| Zynex (ZYXI) | United States | $0.171B | 18.31 |
| Bovie Medical (APYX) | United States | $0.131B | 0.00 |
| Fonar (FONR) | United States | $0.125B | 6.68 |
| Chembio Diagnostics (CEMI) | United States | $0.121B | 0.00 |
| Surface Oncology (SURF) | United States | $0.113B | 0.00 |
| Female Health (VERU) | United States | $0.088B | 0.00 |
| United-Guardian (UG) | United States | $0.088B | 20.06 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.070B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Senestech (SNES) | United States | $0.034B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.025B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 13.71 |
